First line diagnostic test for dyspepsia in Primary Care

 

Dyspepsia is a universal clinical problem affecting 20-40% of the population and carrying an economic impact of £500m per year. Symptoms related to the stomach account for around 4% of all GP consultations and while half of these appointments are for functional (non-ulcer) dyspepsia, functional gastrointestinal disorders constitute 40% of all gastrointestinal referrals.

 

Following referral for endoscopy, the diagnostic yield is often low with 50-70% of Gastroscopies identifying no pathology. At a time when there is an ever increasing burden on endoscopy resources and pressure to improve quality standards in endoscopy there is a growing need for tests that help manage patients with gastric symptoms in Primary Care prior to referral.

 

What is GastroPanel?

 

GastroPanel® is a blood test for dyspeptic patients presenting with stomach complaints. By measuring four stomach-specific biomarkers it transforms patient management by identifying patients who are at risk of diseases characterised by or related to Atrophic Gastritis including:

 

  • Gastric Cancer

  • Gastric Ulcer

  • Acid dysregulation

  • Vitamin and micronutrient deficiency

 

This enables GPs to confidently identify patients that should be referred for specialist opinion by classifying patients according to risk.

 

GastroPanel® identifies the highest known risk factor for Gastric Cancer (GCa) – a progressive condition called Atrophic Gastritis which is caused by Helicobacter pylori infection and autoimmune disease. This pre-neoplastic condition can now be diagnosed easily alongside H. pylori by means of this simple blood test in primary care.

 

Identifying significant disease earlier

 

Atrophic Gastritis is a high-risk, chronic inflammatory condition of the gastric mucosa and is considered the most important risk factor for Gastric Cancer (GCa) with 18% of Atrophic Gastritis cases progressing to cancer within 10 years. By targeting endoscopy resources towards those patients with the greatest risk experts agree that it is possible to diagnose diseases sooner, deliver major improvements in survival in a cost-effective way, and help reach the desired quality standards in endoscopy.

 

Diagnosing Atrophic Gastritis in Primary Care

 

The GastroPanel® blood test is a laboratory assay that accurately identifies Atrophic Gastritis from a plasma sample by measuring four stomach-specific biomarkers. GastroPanel® is a first-line diagnostic test for adults with dyspepsia in Primary Care and importantly, it fits seamlessly into existing pathways for dyspepsia. GastroPanel® overcomes the limitations of stand-alone Helicobacter pylori tests too by enabling the physician to exclude, or, make a diagnosis of Atrophic Gastritis which would otherwise only be possible via invasive gastroscopy. This extra information is valuable for patient management, helping GPs with decisions such as whether to refer the patient, and making better use of available healthcare resources. GastroPanel® is non-invasive, low-cost and extensively validated, and can help physicians select and prioritise Gastroscopy for patients who need it.

 

How does GastroPanel change day to day management of dyspepsia?

 

When patients present with dyspepsia the symptoms are often non-specific, making the diagnosis very difficult and heavily reliant on family history, lifestyle and clinical assessment. GastroPanel® is a very effective tool that provides details about the structure and function of the gastric mucosa, and identifies high-risk Atrophic Gastritis without the need for gastroscopy. By using GastroPanel® first, the GP and patient are presented with three options to consider, directed by a simple algorithm - Manage in Primary Care, Treat, or Refer for Endoscopy.

 

Request the GastroPanel® blood test for patients with symptoms of dyspepsia and receive a risk assessment and accurate profile of your patient’s stomach health, before referral for gastroscopy.

 

GastroPanel® consists of four assays:

 

  • Pepsinogen I ELISA

  • Pepsinogen II ELISA

  • Gastrin-17 ELISA

  • Helicobacter pylori IgG ELISA

 

Use GastroPanel® to: 

 

  • Reliably detect high-risk atrophic gastritis and H. pylori infection;

  • Find patients with hypochlorhydric (low acid) stomach;

  • Identify and refer patients who need gastroscopy;

  • Find patients with a healthy gastric mucosa.

 

Risks associated with atrophic gastritis:

 

  • Gastric cancer (sequel to corpus and/or antral atrophy); 

  • Achlorhydria or Hypochlorhydria;

  • Malabsorption of vitamin B12, calcium, magnesium, zinc, iron and some medicines (corpus atrophy);

  • Colonisation of the stomach by microbes.

 

Helicobacter pylori infection is an independent risk factor for both gastric cancer and peptic ulcer disease. For more information about the GastroPanel, please visit www.gastropanel.com

Unified GastroPanel (Pepsinogen I, Pepsinogen II, H. pylori IgG and Gastrin-17 ELISAs)

Product Code

606400

Clinical Background

Index

© 2018 BIOHIT HealthCare Ltd

Contact Us

BIOHIT HealthCare Ltd

Pioneer House, Pioneer Business Park

North Road

Ellesmere Port

Cheshire CH65 1AD

United Kingdom

Tel: +44 151 550 4 550

Fax: +44 151 550 4 551

cs@biohithealthcare.co.uk

  • Twitter Social Icon